PO.MCB06.03 · 分子与细胞生物学

一种用于液体活检中超短 cfDNA 片段组学和多组学分析的新型工作流程

A novel workflow for ultra short cfDNA fragmentomics and multiomic profiling in liquid biopsies

海报缩略图:一种用于液体活检中超短 cfDNA 片段组学和多组学分析的新型工作流程
编号 3211 展板 21 时间 4/20 02:00–05:00 区域 Section 20 主讲 Xiaojing Yang, PhD
分会场 Epigenetic Changes as Molecular Markers of Cancer
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Xiaojing Yang1, Madison Valle1, Duang Ratanachan1, Kaitlyn Lee1, Neeti Swarup2, Irene Choi2, Hanjun Kim1, David T. Wong2

1Zymo Research Corp., Irvine, CA,2University of California, Los Angeles, Los Angeles, CA

摘要 Abstract

中文摘要
背景:液体活检基质——包括血浆、血清、唾液和尿液——正越来越多地用于非侵入性癌症检测、伴随诊断和复发监测。然而,传统的基于柱的纯化和双链 DNA 文库制备无法捕获完整的 cfDNA 全貌,尤其是超短片段和单链 DNA(ssDNA)。我们评估了一种新型核酸纯化方法,并与一种兼容 ssDNA 的文库制备工作流程配对,以实现更全面的 cfDNA 分析,并以血清和唾液样本作为模型系统。 结果:我们比较了几种市售的基于磁珠的 cfDNA 提取方法。采用新型核酸结合表面的 MAGicBead cfDNA 分离试剂盒产生了最高的 cfDNA 回收率。回收的 cfDNA 使用源自原始拼接连接接头标记(SPLAT)化学的文库制备工作流程进行处理,能够同时捕获 dsDNA 和 ssDNA。在比对的读长中观察到一个独特的超短 DNA 片段群体(35-75 bp),仅在 MAGicBead 纯化时才能检测到,而占主导地位的核小体相关峰得以保留。为确定这些超短片段是否为单链,在文库制备前将分离的 cfDNA 用单链特异性核酸酶处理。消化后,短片段信号不再可检测到,证实了其 ssDNA 性质,并强调了对兼容 ssDNA 的 SPLAT 衍生工作流程的需求。我们接下来将优化后的工作流程应用于肺癌患者的血浆,观察到与健康对照相比超短 cfDNA 片段比例的差异,提示其潜在的片段组学效用。由于唾液因人-微生物混合成分和异质性片段化而成为一种新兴但技术上具挑战性的液体活检基质,我们进一步在唾液中评估了该工作流程。ssDNA 片段群体再次被回收,测序同时揭示了微生物特征,表明该工作流程能在单次运行中同时捕获宿主和微生物 DNA,并支持一种可能提升诊断性能的多组学方法。 结论:MAGicBead cfDNA 分离试剂盒与 SPLAT DNA 文库制备相结合,能够稳健回收传统工作流程通常会丢失的超短 cfDNA 片段。该方法支持在核小体尺寸范围及以下进行全面的 cfDNA 分析。我们的初步研究揭示了以往未被识别的 cfDNA 特征,并指向用于癌症诊断和生物标志物发现的更敏感策略。
查看英文原文 English abstract
Background: Liquid biopsy matrices-including plasma, serum, saliva, and urine-are increasingly used for non-invasive cancer detection, companion diagnostics, and recurrence monitoring. However, conventional column-based purification and double-stranded DNA library preparation fail to capture the full cfDNA landscape, particularly ultra-short fragments and single-stranded DNA (ssDNA). We evaluated a novel nucleic acid purification method paired with an ssDNA-compatible library preparation workflow to enable more comprehensive cfDNA profiling, serum and saliva samples as model systems. Results: We compared several commercially available bead-based cfDNA extraction methods. The MAGicBead cfDNA Isolation Kit, which incorporates a novel nucleic-acid-binding surface, yielded the highest cfDNA recovery. Recovered cfDNA was processed using a library preparation workflow derived from the original Splinted Ligation Adapter Tagging (SPLAT) chemistry, enabling capture of both dsDNA and ssDNA. A distinct population of ultra-short DNA fragments (35-75 bp) was observed in the mapped reads and was detected only with MAGicBead purification, while the dominant nucleosome-associated peak was retained.To determine whether these ultra-short fragments were single-stranded, isolated cfDNA was treated with a single-strand-specific nuclease prior to library preparation. Following digestion, the short-fragment signal was no longer detectable, confirming their ssDNA nature and underscoring the need for an ssDNA-compatible SPLAT-derived workflow.We next applied the optimized workflow to plasma from lung cancer patients and observed differences in the proportion of ultra-short cfDNA fragments relative to healthy controls, suggesting potential fragmentomic utility.Because saliva is an emerging but technically challenging liquid biopsy matrix due to mixed human-microbial content and heterogeneous fragmentation, we further evaluated the workflow in saliva. The ssDNA fragment population was again recovered, and sequencing simultaneously revealed microbial signatures, demonstrating that the workflow captures both host and microbial DNA in a single run and supports a multi-omic approach that may enhance diagnostic performance. Conclusions: The MAGicBead cfDNA Isolation Kit, combined with SPLAT DNA library preparation, enables robust recovery of ultra-short cfDNA fragments that are routinely lost with conventional workflows. This approach supports comprehensive cfDNA profiling across and below the nucleosome-size range. Our pilot studies reveal previously unrecognized cfDNA features and point toward more sensitive strategies for cancer diagnostics and biomarker discovery.
利益披露 Disclosure
X. Yang, None.. M. Valle, None.. D. Ratanachan, None.. K. Lee, None.. N. Swarup, None.. I. Choi, None.. H. Kim, None.. D. T. Wong, None.

← 返回 AACR 2026 检索